Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02292706 · ClinicalTrials.gov registry record

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

A clinical trial, sponsored by Gilead Sciences.

Terminated
Registry status
1,609
Enrollment target

NCT02292706: Clinical Trial study, sponsored by Gilead Sciences.

NCT02292706 is a clinical trial that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 1,609 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02292706 was terminated before completion, sponsored by Gilead Sciences.

TERMINATED
Registry status
1,609 participants
Enrollment target

Study Summary

The primary objective of this registry study is to assess the durability of sustained virologic response (SVR) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following SVR in participants with cirrhosis after treatment with a sofosbuvir-based regimen for HCV infection.

Primary Outcome

SVR at Week 240 was defined as HCV RNA\< lower limit of quantification (LLOQ i.e., 15 or 25 international units per milliliter \[IU/mL\]) or last available HCV RNA\< LLOQ with no subsequent follow-up values at Week 240 after enrollment in this registry study. Percentage of participants who maintained SVR status by Week 240 was estimated using a Kaplan-Meier model.

Interventions

  • DRUG Ribavirin
  • DRUG Sofosbuvir
  • DRUG LDV/SOF
  • DRUG SOF/VEL/VOX
  • DRUG SOF/VEL

Trial Details

FieldValue
Enrollment Target 1,609 participants
Start Date 2014-12-29
Est. Completion 2021-12-31
Gilead Sciences

504 total trials

Why NCT02292706 stopped before completion

NCT02292706 is an observational study that tracks outcomes without assigning an intervention. Its 1,609 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.

NCT02292706 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02292706 about?

NCT02292706 is a clinical study titled "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection". The primary objective of this registry study is to assess the durability of sustained virologic response (SVR) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following SVR in participants with cirrhosis after treatment with a sofosbuvir-ba...

What is the current status of trial NCT02292706?

This trial is currently terminated. The enrollment target is 1,609 participants. The study started on 2014-12-29. Estimated completion is 2021-12-31.

What interventions are being tested in trial NCT02292706?

The interventions under investigation include: Ribavirin (DRUG), Sofosbuvir (DRUG), LDV/SOF (DRUG), SOF/VEL/VOX (DRUG), SOF/VEL (DRUG).

Who is sponsoring clinical trial NCT02292706?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06271590 · 1,605 participants · NA

    MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

  • NCT06959524 · 1,616 participants · NA

    AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  • NCT00646022 · 1,600 participants

    Natural History of Familial Carcinoid Tumor

  • NCT03109197 · 1,600 participants

    Sudden Unexplained Death in Childhood (SUDC) Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02292706, the US trial registry maintained by the National Library of Medicine. NCT02292706 (large enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.